Literature DB >> 14522862

Molecular and clinical classification of human prion disease.

Jonathan D F Wadsworth1, Andrew F Hill, Jonathan A Beck, John Collinge.   

Abstract

While rare in humans, the prion diseases have become an area of intense clinical and scientific interest. The recognition that variant Creutzfeldt-Jakob disease is caused by the same prion strain as bovine spongiform encephalopathy in cattle has dramatically highlighted the need for a precise understanding of the molecular biology of human prion diseases. Detailed clinical, pathological and molecular data from a large number of human prion disease cases have shown that distinct abnormal isoforms of prion protein are associated with prion protein gene polymorphism and neuropathological phenotypes. A molecular classification of human prion diseases seems achievable through characterisation of structural differences of the infectious agent itself.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14522862     DOI: 10.1093/bmb/66.1.241

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  54 in total

1.  Octapeptide repeat insertions increase the rate of protease-resistant prion protein formation.

Authors:  Roger A Moore; Christian Herzog; John Errett; David A Kocisko; Kevin M Arnold; Stanley F Hayes; Suzette A Priola
Journal:  Protein Sci       Date:  2006-02-01       Impact factor: 6.725

2.  The charge structure of helix 1 in the prion protein regulates conversion to pathogenic PrPSc.

Authors:  Eric M Norstrom; James A Mastrianni
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 3.  Insights into intragenic and extragenic effectors of prion propagation using chimeric prion proteins.

Authors:  Heather L True; Tejas Kalastavadi; Elizabeth M H Tank
Journal:  Prion       Date:  2008-04-17       Impact factor: 3.931

4.  Accelerated, spleen-based titration of variant Creutzfeldt-Jakob disease infectivity in transgenic mice expressing human prion protein with sensitivity comparable to that of survival time bioassay.

Authors:  Sophie Halliez; Fabienne Reine; Laetitia Herzog; Emilie Jaumain; Stéphane Haïk; Human Rezaei; Jean-Luc Vilotte; Hubert Laude; Vincent Béringue
Journal:  J Virol       Date:  2014-05-21       Impact factor: 5.103

Review 5.  Clinical Laboratory Tests Used To Aid in Diagnosis of Human Prion Disease.

Authors:  Allyson Connor; Han Wang; Brian S Appleby; Daniel D Rhoads
Journal:  J Clin Microbiol       Date:  2019-09-24       Impact factor: 5.948

6.  First symptom and initial diagnosis in sporadic CJD patients in Germany.

Authors:  Anna Krasnianski; Judith Kaune; Klaus Jung; Hans A Kretzschmar; Inga Zerr
Journal:  J Neurol       Date:  2014-07-15       Impact factor: 4.849

7.  Genetics and genetic counseling: recommendations for Alzheimer's disease, frontotemporal dementia, and Creutzfeldt-Jakob disease.

Authors:  Jennifer Williamson; Susan LaRusse
Journal:  Curr Neurol Neurosci Rep       Date:  2004-09       Impact factor: 5.081

8.  Absence of spontaneous disease and comparative prion susceptibility of transgenic mice expressing mutant human prion proteins.

Authors:  Emmanuel A Asante; Ian Gowland; Andrew Grimshaw; Jacqueline M Linehan; Michelle Smidak; Richard Houghton; Olufunmilayo Osiguwa; Andrew Tomlinson; Susan Joiner; Sebastian Brandner; Jonathan D F Wadsworth; John Collinge
Journal:  J Gen Virol       Date:  2009-03       Impact factor: 3.891

9.  Progressive Stroke-Like Symptoms in a Patient with Sporadic Creutzfeldt-Jakob Disease.

Authors:  Jukka Lyytinen; Tiina Sairanen; Leena Valanne; Tapani Salmi; Anders Paetau; Eero Pekkonen
Journal:  Case Rep Neurol       Date:  2010-03-12

10.  Prevalence of disease related prion protein in anonymous tonsil specimens in Britain: cross sectional opportunistic survey.

Authors:  Jonathan P Clewley; Carole M Kelly; Nick Andrews; Kelly Vogliqi; Gary Mallinson; Maria Kaisar; David A Hilton; James W Ironside; Philip Edwards; Linda M McCardle; Diane L Ritchie; Reza Dabaghian; Helen E Ambrose; O Noel Gill
Journal:  BMJ       Date:  2009-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.